메뉴 건너뛰기




Volumn 44, Issue 1, 2014, Pages 25-30

Up-titration of allopurinol in patients with gout

(20)  Jennings, Claudine G a   Mackenzie, Isla S a   Flynn, Rob a   Ford, Ian b,e   Nuki, George c,e   De Caterina, Raffaele d,e   Riches, Philip L c   Ralston, Stuart H c,e   MacDonald, Thomas M a   Mackenzie, Isla a,e   MacDonald, Thomas a,e   Findlay, Evelyn e   Hallas, Jesper f,i   Hawkey, Chris f,j   Walters, Matthew b,f   Webster, John f,h   McMurray, John f   Ruiz, Fernando Perez g   Riches, Philip c   Harvie, John k  


Author keywords

Allopurinol; Clinical guidelines; Gout; Prescribing

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; URATE; ANTIGOUT AGENT;

EID: 84905224562     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.01.004     Document Type: Article
Times cited : (43)

References (21)
  • 1
    • 46849088805 scopus 로고    scopus 로고
    • Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005
    • Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008, 67:960-966.
    • (2008) Ann Rheum Dis , vol.67 , pp. 960-966
    • Annemans, L.1    Spaepen, E.2    Gaskin, M.3    Bonnemaire, M.4    Malier, V.5    Gilbert, T.6
  • 3
    • 70449721119 scopus 로고    scopus 로고
    • Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007
    • Elliot A.J., Cross K.W., Fleming D.M. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis 2009, 68:1728-1733.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1728-1733
    • Elliot, A.J.1    Cross, K.W.2    Fleming, D.M.3
  • 4
    • 85172827499 scopus 로고    scopus 로고
    • Office of national statistics. National population projections, 〈〉 2012 [accessed May 2013].
    • Office of national statistics. National population projections, 〈〉 2012 [accessed May 2013]. http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2010-based-reference-volume--series-pp2/results.html%23tab-Age-structure.
  • 5
    • 33748608331 scopus 로고    scopus 로고
    • EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)
    • Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1312-1324
    • Zhang, W.1    Doherty, M.2    Bardin, T.3    Pascual, E.4    Barskova, V.5    Conaghan, P.6
  • 6
    • 84869186940 scopus 로고    scopus 로고
    • 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
    • Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64:1431-1446.
    • (2012) Arthritis Care Res , vol.64 , pp. 1431-1446
    • Khanna, D.1    Fitzgerald, J.D.2    Khanna, P.P.3    Bae, S.4    Singh, M.K.5    Neogi, T.6
  • 8
    • 34848884310 scopus 로고    scopus 로고
    • Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations
    • Roddy E., Zhang W.Y., Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007, 66:1311-1315.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1311-1315
    • Roddy, E.1    Zhang, W.Y.2    Doherty, M.3
  • 9
    • 85172829853 scopus 로고    scopus 로고
    • Gout treatment gaps and factors associated with incident patients having uric acid goal attainment: a retrospective cohort study in an integrated healthcare system
    • Rashid N., Cheetham T.C., Curtis J.R., Levy G.D., Saag K.G., Mikuls T.R. Gout treatment gaps and factors associated with incident patients having uric acid goal attainment: a retrospective cohort study in an integrated healthcare system. Arthritis Rheum 2011, 63:S349.
    • (2011) Arthritis Rheum , vol.63
    • Rashid, N.1    Cheetham, T.C.2    Curtis, J.R.3    Levy, G.D.4    Saag, K.G.5    Mikuls, T.R.6
  • 10
    • 0036260510 scopus 로고    scopus 로고
    • Improving the quality of care of musculoskeletal conditions in primary care
    • Roberts C., Adebajo A.O., Long S. Improving the quality of care of musculoskeletal conditions in primary care. Rheumatology 2002, 41:503-508.
    • (2002) Rheumatology , vol.41 , pp. 503-508
    • Roberts, C.1    Adebajo, A.O.2    Long, S.3
  • 11
    • 56049101851 scopus 로고    scopus 로고
    • Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial
    • Schumacher H.R., Becker M.A., Wortmann R.L., MacDonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthrit Care Res 2008, 59:1540-1548.
    • (2008) Arthrit Care Res , vol.59 , pp. 1540-1548
    • Schumacher, H.R.1    Becker, M.A.2    Wortmann, R.L.3    MacDonald, P.A.4    Hunt, B.5    Streit, J.6
  • 13
    • 35448936489 scopus 로고    scopus 로고
    • British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout
    • Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J.R., et al. British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout. Rheumatology 2007, 46:1372-1374.
    • (2007) Rheumatology , vol.46 , pp. 1372-1374
    • Jordan, K.M.1    Cameron, J.S.2    Snaith, M.3    Zhang, W.4    Doherty, M.5    Seckl, J.R.6
  • 15
    • 84877586862 scopus 로고    scopus 로고
    • Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study
    • Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013, 72:826-830.
    • (2013) Ann Rheum Dis , vol.72 , pp. 826-830
    • Rees, F.1    Jenkins, W.2    Doherty, M.3
  • 16
    • 0034088994 scopus 로고    scopus 로고
    • How is gout managed in primary care? A review of current practice and proposed guidelines
    • Pal B., Foxall M., Dysart T., Carey F., Whittaker M. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21-25.
    • (2000) Clin Rheumatol , vol.19 , pp. 21-25
    • Pal, B.1    Foxall, M.2    Dysart, T.3    Carey, F.4    Whittaker, M.5
  • 17
    • 84864486646 scopus 로고    scopus 로고
    • Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol
    • Stamp L.K., Taylor W.J., Jones P.B., Dockerty J.L., Drake J., Frampton C., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012, 64:2529-2536.
    • (2012) Arthritis Rheum , vol.64 , pp. 2529-2536
    • Stamp, L.K.1    Taylor, W.J.2    Jones, P.B.3    Dockerty, J.L.4    Drake, J.5    Frampton, C.6
  • 18
    • 85172829285 scopus 로고    scopus 로고
    • Datapharm. Electronic Medicines Compendium, 〈〉 2013 [accessed May 2013].
    • Datapharm. Electronic Medicines Compendium, 〈〉 2013 [accessed May 2013]. http://www.medicines.org.uk/emc/medicine/23722/SPC.
  • 19
    • 84905219493 scopus 로고    scopus 로고
    • Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol
    • Stamp L.K., Taylor W., Jones P.B.B., Dockerty J.L., Drake J., Frampton C., et al. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol. Arthritis Rheum 2012, 63:S1012.
    • (2012) Arthritis Rheum , vol.63
    • Stamp, L.K.1    Taylor, W.2    Jones, P.B.B.3    Dockerty, J.L.4    Drake, J.5    Frampton, C.6
  • 20
    • 80155198743 scopus 로고    scopus 로고
    • HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency
    • Jung J.W., Song W.J., Kim Y.S., Joo K.W., Lee K.W., Kim S.H., et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011, 26:3567-3572.
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 3567-3572
    • Jung, J.W.1    Song, W.J.2    Kim, Y.S.3    Joo, K.W.4    Lee, K.W.5    Kim, S.H.6
  • 21
    • 0021366307 scopus 로고
    • Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency
    • Hande K., Noone R., Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
    • (1984) Am J Med , vol.76 , pp. 47-56
    • Hande, K.1    Noone, R.2    Stone, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.